Eli Lilly

US pharma major Eli Lilly to establish second Indian GCC in Hyderabad

Company plans to employ 1,000-1,500 skilled professionals; GCC to focus on automation, AI

Eli Lilly to set up global capability centre in Hyderabad, hire 1K people

Pharma major Eli Lilly and Company on Thursday said it plans to establish a new global capability centre in Hyderabad and hire over 1,000 people to strengthen its digital strategy and service delivery. The Hyderabad global capability centre (GCC) will be known as Lilly Capability Centre India (LCCI) Hyderabad and will initially focus on expanding Lilly's capabilities in automation, artificial intelligence, software product engineering and cloud computing to deliver advanced technology solutions that meet the evolving needs of Lilly's business worldwide, the Eli Lilly and Company (Lilly) said in a statement. Lilly will be recruiting more than 1,000 highly-skilled team members to strengthen the company's digital strategy and service delivery, it added. The company further said it plans to employ around 1,000 to 1,500 highly-skilled professionals including technology engineers and data scientists. Recruitment for the new site is underway, and the centre is expected to be operational b

In weight loss battle, Novo and Lilly face offensive from licenced copies

Since Novo's blockbuster Ozempic diabetes treatment was approved in the United States in 2017, regulators have greenlighted 22 medicines containing its main ingredient in Bangladesh, Laos, Russia

Eli Lilly's weight-loss, diabetes drug shortage is resolved, says US FDA

The finding effectively bars widespread sales of cheaper copies of the drugs that many patients use, but the FDA said it would not take any action against the compounding pharmacies

Eli Lilly to launch its obesity drug at competitive price in India in 2025

Lilly's rival Danish firm Novo Nordisk is also working to bring its obesity drug Wegovy (Semaglutide) to India soon, and according to reports the company may launch Wegovy in 2026

Eli Lilly to boost weight-loss drug supply with $3 billion expansion

The company's s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world

Novo Nordisk India execs urge early Wegovy launch as rival Eli Lilly looms

Novo and Lilly are both scaling up production as they vie for a dominant share of a weight-loss market that some analysts forecast could reach $150 billion a year in the next decade

Novo Nordisk aware of deaths linked to compounded weight-loss drug copies

This was a result of significant investments to expand its manufacturing capacity and "ongoing communication" with the FDA, the company said at the time

Novo Nordisk posts Q3 sales of obesity drug Wegovy above expected forecast

The Denmark-based company said it now expects sales growth this year of between 23% and 27% in local currencies, compared to the previously guided range for 22% to 28% growth

Eli Lilly's blockbuster weight-loss drug no longer in shortage in US: USFDA

The shortage of all doses of the drug, tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight management has been resolved

Novo Nordisk pares 2024 profit outlook amid competition from Eli Lilly

The Danish company lowered its forecast for operating profit growth this year to between 20% and 28% in local currencies, compared to its previous forecast of 22% to 30%

Eli Lilly's popular drug Mounjaro stuck at Indian regulators' counter

Eli Lilly's Mounjaro, a blockbuster diabetes medication and a highly popular obesity treatment is still awaiting approval from CDSCO despite a SEC clearance

Explained: Eli Lilly's 'miracle' weight-loss drug soon to enter India

The American pharmaceutical giant is set to introduce its obesity drug, a competitor to Nova Nordisk's Ozempic, in India as early as next year

Eli Lilly expects to launch obesity drug in India next year, says CEO

Mounjaro, chemically known as tirzepatide, is currently sold in the UK and Europe under the same brand name for both conditions

Eli Lilly closer to joining Magnificent Seven in $1 trn market cap club

"Could Lilly be the first $1 trillion biopharma stock?" Morgan Stanley's Terence Flynn and colleagues asked in a note to clients. "We continue to see a path for further upside"

USFDA finds new manufacturing lapses at pharma co Eli Lilly's plant: Report

Lilly said in a statement to Reuters that the inspection followed a company request to the FDA to make a change to its manufacture of migraine treatment Emgality

Eli Lilly's 'triple G' anti-obesity drug leads to 24% weight loss in trial

The pharma company published the results of phase two of the clinical trial of Retatrutide, showing impressive weight loss and regulation of blood sugar levels in undertrials

Suven starts Phase 3 trial for first home-grown Alzheimer's drug

Clinical trial randomisation is the process of assigning patients by chance to groups that receive different treatments

What is Twitter's blue tick?

Twitter's move to sell its blue check badge for $8 made aerospace company Lockheed Martin and pharma giant Eli Lilly & Co fall prey to impersonators. What is blue check? How did it come into being?

Twitter's big headache: Brand impostors thanks to the $8 verification

Users started creating accounts pretending to be major brands and politicians, fooling users and potentially jeopardizing Twitter's now-shaky reputation with top advertisers